Effect of glitazones on the progression of coronary artery disease in type 2 diabetes patients

References

• NarayanKMBoyleJPGeissLSSaaddineJBThompsonTJImpact of recent increase in incidence on future diabetes burden: US, 2005–2050Diabetes Care20062992114211616936162
   PubMed Web of Science ®Google Scholar
• FoxCSPencinaMJWilsonPWPaynterNPVasanRSD’AgostinoRBSrLifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart studyDiabetes Care20083181582158418458146
   PubMed Web of Science ®Google Scholar
• NarayanKMBoyleJPThompsonTJGreggEWWilliamsonDFEffect of BMI on lifetime risk for diabetes in the USDiabetes Care20073061562156617372155
   PubMed Web of Science ®Google Scholar
• JuutilainenALehtoSRönnemaaTPyöräläKLaaksoMSimilarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjectsDiabetes Care200831471471918083789
   PubMed Web of Science ®Google Scholar
• WhiteleyLPadmanabhanSHoleDIslesCShould diabetes be considered a coronary heart disease risk equivalent?: results from 25 years of follow-up in the Renfrew and Paisley surveyDiabetes Care20052871588159315983305
   PubMed Web of Science ®Google Scholar
• GorayaTYLeibsonCLPalumboPJCoronary atherosclerosis in diabetes mellitus: a population-based autopsy studyJ Am Coll Cardiol200240594695312225721
   PubMed Web of Science ®Google Scholar
• XiangLDearmanJAbramSRCarterCHesterRLInsulin resistance and impaired functional vasodilation in obese Zucker ratsAm J Physiol Heart Circ Physiol20082944H1658H66618296567
   PubMed Web of Science ®Google Scholar
• TraupeTD’UscioLVMuenterKMorawietzHVetterWBartonMEffects of obesity on endothelium-dependent reactivity during acute nitric oxide synthase inhibition: modulatory role of endothelinClin Sci (Lond)2002103Suppl 4813S15S12193045
   PubMedGoogle Scholar
• TraupeTLangMGoettschWObesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expressionJ Hypertens200220112239224512409963
   PubMed Web of Science ®Google Scholar
• GollaschMEndothelium-derived contracting factor: a new way of looking at endothelial function in obesityJ Hypertens200220112147214912409950
   PubMed Web of Science ®Google Scholar
• ShiYSoKFManRYVanhouttePMOxygen-derived free radicals mediate endothelium-dependent contractions in femoral arteries of rats with streptozotocin-induced diabetesBr J Pharmacol200715271033104117767168
   PubMed Web of Science ®Google Scholar
• TesfamariamBBrownMLCohenRAElevated glucose impairs endothelium-dependent relaxation by activating protein kinase CJ Clin Invest1991875164316482022734
   PubMed Web of Science ®Google Scholar
• BurkeAPKolodgieFDZieskeAMorphologic findings of coronary atherosclerotic plaques in diabetics:a postmortem studyArterioscler Thromb Vasc Biol200424712661267115142859
   PubMed Web of Science ®Google Scholar
• HongYJJeongMHChoiPlaque characteristics in culprit lesions and inflammatory status in diabetic acute coronary syndrome patientsJACC Cardiovasc Imaging20092333934919356580
   PubMed Web of Science ®Google Scholar
• TangTYHowarthSPMillerSRThe ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid diseaseJ Am Coll Cardiol20092532220392035019477353
   PubMedGoogle Scholar
• IssemannIGreenSActivation of a member of the steroid hormone receptor superfamily by peroxisome proliferatorsNature199034762946456502129546
   PubMed Web of Science ®Google Scholar
• KeechASimesRJBarterPFIELD study investigatorsEffects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialLancet2005366950018491861 Erratum in: Lancet. 2006;368(9545):1415. Lancet. 2006;368(9545):142016310551
   PubMed Web of Science ®Google Scholar
• de LorgerilMSalenPPaillardFLacanPRichardGLipid-lowering drugs and homocysteineLancet199935391482092109923885
   PubMed Web of Science ®Google Scholar
• MikaelLGGenestJJrRozenRElevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery diseaseCirc Res200698456457116439690
   PubMed Web of Science ®Google Scholar
• NissenSENichollsSJWolskiKPERISCOPE InvestigatorsComparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trialJAMA20082991315611507318378631
   PubMed Web of Science ®Google Scholar
• ChiquetteERamirezGDefronzoRA meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factorsArch Intern Med2004164192097210415505122
   PubMedGoogle Scholar
• GoldbergRBKendallDMDeegMAGLAI Study InvestigatorsA comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemiaDiabetes Care20052871547155415983299
   PubMed Web of Science ®Google Scholar
• OrasanuGZiouzenkovaODevchandPRThe peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in miceJ Am Coll Cardiol2008521086988118755353
   PubMed Web of Science ®Google Scholar
• BogackaIXieHBrayGASmithSRThe effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivoDiabetes Care20042771660166715220243
   PubMed Web of Science ®Google Scholar
• OsmanAOteroJBrizolaraAEffect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetesAm Heart J20041475e2315131558
   PubMed Web of Science ®Google Scholar
• MarxNFroehlichJSiamLAntidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery diseaseArterioscler Thromb Vasc Biol200323228328812588772
   PubMed Web of Science ®Google Scholar
• ParkKSCiaraldiTPAbrams-CarterLMudaliarSNikoulinaSEHenryRRPPAR-gamma gene expression is elevated in skeletal muscle of obese and type II diabetic subjectsDiabetes1997467123012349200661
   PubMed Web of Science ®Google Scholar
• BergerJLeibowitzMDDoebberTWNovel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effectsJ Biol Chem1999274106718672510037770
   PubMed Web of Science ®Google Scholar
• OliverWRJrShenkJLSnaithMRA selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transportProc Natl Acad Sci U S A20019895306531111309497
   PubMed Web of Science ®Google Scholar
• LiACBinderCJGutierrezADifferential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha,beta/delta, and gammaJ Clin Invest2004114111564157615578089
   PubMed Web of Science ®Google Scholar
• NissenSENichollsSJWolskiKPERISCOPE InvestigatorsComparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trialJAMA2008299131561157318378631
   PubMed Web of Science ®Google Scholar
• RatnerRECannonCPGersteinHCAPPROACH Study GroupAssessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristicsAm Heart J200815661074107919033001
   PubMed Web of Science ®Google Scholar
• NestoRWAssessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Type 2 Diabetes patients with Cardiovascular History (APPROACH) American Heart Association 2008 Scientific Sessions; November 12, 2008; New Orleans, LA. Late Breaking Clinical Trials Session 4
   Google Scholar
• GoldbergRBKendallDMDeegMAGLAI Study InvestigatorsA comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemiaDiabetes Care20052871547155415983299
   PubMed Web of Science ®Google Scholar
• MazzoneTMeyerPMFeinsteinSBEffect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trialJAMA2006296212572258117101640
   PubMed Web of Science ®Google Scholar
• DormandyJACharbonnelBEcklandEJASecondary prevention of macrovascular events in patients with type 2 diabetes: a randomized trial of pioglitazone. The PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events)Lancet200536694931279128916214598
   PubMed Web of Science ®Google Scholar
• HomePDPocockSJBeck-NielsenHRosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomized, open-label trialLancet200937396812125213519501900
   PubMed Web of Science ®Google Scholar
• VillardJWParanjapeASVictorDAFeldmanMDApplications of optical coherence tomography in cardiovascular medicineJ Nucl Cardiol200916462063919479314
   PubMed Web of Science ®Google Scholar